LB Pharmaceuticals Inc

LB Pharmaceuticals Inc (LBRX) priced its initial public offering on Sep 12, 2025 at $15.00 per share, within its $14.00–$16.00 range, raising $285M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $336.6M. Leerink Partners was lead-left underwriter, joined by Piper Sandler and Stifel. Cooley advised the company and Mintz advised the underwriters.

LB PHARMACEUTICALS INC is a clinical-stage biopharmaceutical company developing therapies for schizophrenia, bipolar depression and other neuropsychiatric diseases. Its lead candidate, LB-102, is a methylated derivative of amisulpride, a second-generation antipsychotic.

Status

IPO

Ticker

LBRX

Exchange

Nasdaq Global Market

Priced

Sep 12, 2025

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$285M

Market cap at IPO price

$336.6M

First filed

Aug 22, 2025

Underwriters

Leerink Partners, Piper Sandler and Stifel

Company counsel

Cooley

Underwriters' counsel

Mintz

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.